SCHEMBL4387753

SCHEMBL4387753

CCOC(=O)c1sc(-c2ccnc(Nc3ccc(Cl)cc3)n2)nc1O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 7/20 0.62
DBF4 Q9UBU7 7/20 0.62
TRPM8 Q7Z2W7 6/20 0.61
MAPT P10636 4/20 0.61
KDM4E B2RXH2 2/20 0.54
CDK2 P24941 1/20 0.49
ALK Q9UM73 1/20 0.48
DHODH Q02127 1/20 0.48
PIK3CA P42336 1/20 0.47
PIK3CB P42338 1/20 0.47
PIK3CG P48736 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
NPC1 O15118 1/20 0.46
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4387241 0.91 LMNA (0.55) CDC7DBF4TRPM8MAPTKDM4E
SCHEMBL4393948 0.89 CDC7 (0.59) CDC7DBF4TRPM8MAPTKDM4E
SCHEMBL4389830 0.84 CDK2 (0.47) CDC7DBF4TRPM8MAPTKDM4E
SCHEMBL4391861 0.84 CDK2 (0.50) CDC7DBF4CDK2PIK3CAPIK3CB
SCHEMBL4386260 0.79 CDK2 (0.51) KDM4ECDK2ALKPIK3CAPIK3CB
SCHEMBL4385796 0.79 CDK2 (0.58) MAPTKDM4ECDK2PIK3CAPIK3CB
SCHEMBL4389627 0.79 CDK2 (0.58) MAPTCDK2PIK3CAPIK3CBPIK3CG
SCHEMBL14216051 0.78 ZAP70 (0.67) CDC7DBF4MAPTKDM4ECDK2
SCHEMBL15048955 0.77 TRPM8 (1.00) CDC7DBF4TRPM8MAPTKDM4E
SCHEMBL3949128 0.75 SYK (0.69) CDK2MEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US claimed
EP-1751146-A2 PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY Cyclacel Limited (GB) 2007-02-14 EP claimed
CN-1914199-A Pyridyl or pyrimidyl thiazole compounds having protein kinase inhibitory activity CYCLACEL LTD (GB) 2007-02-14 CN claimed
WO-2005075468-A2 PYRIDINYL - OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LIMITED (GB) 2005-08-18 WO claimed
EP-1751146-B1 PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LTD (GB) 2009-12-02 EP disclosed
EP-1751146-B1 PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LTD (GB) 2009-12-02 EP disclosed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US disclosed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US disclosed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US disclosed
EP-1751146-A2 PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY Cyclacel Limited (GB) 2007-02-14 EP disclosed
CN-1914199-A Pyridyl or pyrimidyl thiazole compounds having protein kinase inhibitory activity CYCLACEL LTD (GB) 2007-02-14 CN disclosed
WO-2005075468-A2 PYRIDINYL - OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LIMITED (GB) 2005-08-18 WO disclosed
WO-2005075468-A2 PYRIDINYL - OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LIMITED (GB) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318954-A1 Compounds CBR3, NR3C2, NR5A1 CDC7 1258/4885DBF4 1294/4885TRPM8 1086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.